Sign In
Buy VCYT
$48.69
+0.89 (+1.86%)
At Close: Jun 03, 2026
Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands
08:46am, Friday, 23'rd Feb 2024
Veracyte's (VCYT) fourth-quarter 2023 performance reflects solid financial discipline and the strength of the Decipher Prostate and Afirma tests.
Veracyte, Inc. (VCYT) Q4 2023 Earnings Call Transcript
09:24pm, Thursday, 22'nd Feb 2024
Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Conference Call February 22, 2024 4:30 PM ET
Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates
07:06pm, Thursday, 22'nd Feb 2024
Veracyte (VCYT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.05 per share a year ago.
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
04:05pm, Thursday, 22'nd Feb 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2023. “We closed 2023 with anoth
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
05:00pm, Wednesday, 21'st Feb 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and John Leite, Ph.D., chief commercial officer, CLIA, will pres
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
08:00am, Thursday, 08'th Feb 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year 2023 after the close of market o
Veracyte Completes Acquisition of C2i Genomics
08:15am, Tuesday, 06'th Feb 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Completes Acquisition of C2i Genomics.
3 Medical Instruments Stocks to Buy as Industry Trends Improve
11:16am, Tuesday, 23'rd Jan 2024
The Zacks Medical - Instruments industry is gaining from the rising demand for digital health offers. However, inflation and staffing shortages continue to disrupt growth.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary unaudited financial results for the fourth quarter and fu
5 Top-Ranked Cathie Wood Stocks to Buy Right Now
09:47am, Thursday, 04'th Jan 2024
Here, we have picked five Cathie Wood stocks, Palantir (PLTR), Veracyte (VCYT), PagerDuty (PD), Roku (ROKU) and UiPath (PATH), which are well-poised for healthy returns in 2024.
Veracyte, Inc. (VCYT) Q3 2023 Earnings Call Transcript
08:57pm, Tuesday, 07'th Nov 2023
Veracyte, Inc. (NASDAQ:VCYT ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Tristan Ribar – Vice President-Finance Marc Stapley – Chief Executive Officer Rebecc
7 Undervalued Stocks That Analysts Love Right Now
02:50pm, Thursday, 26'th Oct 2023
Ahead of possible volatility in the market, investors may find some measure of confidence in undervalued stocks. From a psychological perspective, companies that sit well outside the well-beaten path
Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors?
06:15am, Saturday, 02'nd Sep 2023
Veracyte's revenue sharply rose in the second quarter. The company is moving toward profitability.
Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates
07:42pm, Tuesday, 08'th Aug 2023
Veracyte (VCYT) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.13 per share a year ago.
Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023
05:00pm, Wednesday, 19'th Jul 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2023 after the close of market on Tuesday,
